Medically reviewed by Dr. Samuel Sarmiento, M.D., MPH on August 3, 2023 Explore this cutting-edge development in vitiligo treatment. Ruxolitinib, a new FDA-approved medication, offers patients a promising tool for repigmentation. Ruxolitinib is the first FDA-approved topical medication specifically for repigmentation in patients with non-segmental vitiligo. In recent clinical trials, over half of the patients...